The paper identifies a proteomic signature of mantle cell lymphoma (MCL) using quantitative proteomics, revealing 10 upregulated proteins that may serve as therapeutic targets.

bioRxiv · Apr 27, 2026 · PreprintCancer Biology

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma

Sunandini Sharma, Roshia Ali, Alyssa C. Bouska, Dylan T. Jochum, Meghana Kesireddy, Simeon Mahov, Joseph Cornelius Lownik, Weiwei Zhang, Waseem Lone, Mahfuza Afroz Soma, Alicia Gamboa, Vaishnavi Devarakonda, Dalia El‐Gamal, Atqiya Fariha, Adnan Mansoor, , On behalf of the North American Mantle Cell Lymphoma Project (NAMCLP)

The paper identifies prognostic biological subtypes in Mantle cell lymphoma based on genetic and transcriptomic analysis, revealing distinct molecular and immune features associated with different risk groups.

Nature Communications · Nov 5, 2025Peer-reviewedCancer Biology

Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects

Alexandria P. Eiken, Audrey L. Smith, Sydney A. Skupa, Elizabeth Schmitz, Sandeep Rana, Sarbjit Singh, Siddhartha Kumar, Jayapal Reddy Mallareddy, Aguirre A de Cubas, Akshay Krishna, Achyuth Kalluchi, M. Jordan Rowley, Christopher R. D'Angelo, Matthew A. Lunning, R. Gregory Bociek, , Dalia El-Gamal

This paper evaluates SpiD3, a novel spirocyclic dimer, showing potent anti-leukemic effects in CLL cells, including resistance to ibrutinib, by targeting NF-κB signaling and the UPR.

bioRxiv · Jan 31, 2024Cancer Biology

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

Man Chun John Ma, Saber Tadros, Alyssa C. Bouska, Tayla B. Heavican, Haopeng Yang, Qing Deng, Dalia Y. Moore, Ariz Akhter, Keenan T. Hartert, Neeraj Kumar Jain, Jordan Showell, Sreejoyee Ghosh, Lesley E. Street, Marta Beata Davidson, Christopher Daniel Carey, , Michael R. Green

This study identifies subtype-specific and co-occurring genetic alterations across major B-NHL subtypes using targeted sequencing of 380 genes in 685 tumors.

Haematologica · Apr 1, 2021Peer-reviewedGenomics

Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma

Neeraj Kumar Jain, Keenan T. Hartert, Saber Tadros, Warren C. Fiskus, Ondřej Havránek, Man Chun John Ma, Alyssa C. Bouska, Tayla B. Heavican, Dhiraj Kumar, Qing Deng, Dalia Y. Moore, Christine J. Pak, Chih Long Liu, Andrew J. Gentles, Elena Hartmann, , Michael R. Green

The paper identifies TCF4 overexpression driven by 18q21.2 gains as a mechanism promoting IgM expression in ABC-like DLBCL and shows BET inhibitors can suppress it.

Science Translational Medicine · Jun 19, 2019Peer-reviewedGenomics